Odyssey Therapeutics (NASDAQ:ODTX) Releases Quarterly Earnings Results

Odyssey Therapeutics (NASDAQ:ODTX) announced its quarterly earnings results on Wednesday. The company reported ($1.74) earnings per share (EPS) for the quarter, FiscalAI reports.

Odyssey Therapeutics Price Performance

Shares of Odyssey Therapeutics stock traded up $0.03 during trading on Friday, hitting $21.58. The company’s stock had a trading volume of 34,828 shares, compared to its average volume of 313,409. Odyssey Therapeutics has a 52 week low of $15.10 and a 52 week high of $22.26. The business’s fifty day moving average price is $17.78.

Analysts Set New Price Targets

ODTX has been the topic of several research analyst reports. Oppenheimer restated an “outperform” rating and issued a $40.00 price objective on shares of Odyssey Therapeutics in a research note on Thursday, June 18th. JPMorgan Chase & Co. increased their target price on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday. Zacks Research raised Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. Wedbush initiated coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 price target on the stock. Finally, TD Cowen began coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set a “buy” rating on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $33.00.

Insider Buying and Selling

In related news, Director Shelley Chu purchased 11,111 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $18.00 per share, with a total value of $199,998.00. Following the acquisition, the director owned 11,111 shares in the company, valued at $199,998. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Tpg Gp A, Llc acquired 1,388,889 shares of Odyssey Therapeutics stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $18.00 per share, for a total transaction of $25,000,002.00. Following the transaction, the insider owned 3,690,146 shares of the company’s stock, valued at $66,422,628. This represents a 60.35% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 3,066,666 shares of company stock worth $55,199,988.

About Odyssey Therapeutics

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.